What is Initial Therapeutics?
Based in South San Francisco, California, Initial Therapeutics is dedicated to pioneering a new class of small-molecule drugs aimed at preventing the synthesis of disease-causing proteins. The company's innovative approach targets fundamental biological processes, positioning it at the forefront of therapeutic development in its sector. The recent enterprise-level funding signifies strong investor confidence in its scientific foundation and its potential to address significant unmet medical needs.
How much funding has Initial Therapeutics raised?
Initial Therapeutics has raised a total of $75M across 1 funding round:
Series A
$75M
Series A (2023): $75M with participation from Apple Tree Partners
Key Investors in Initial Therapeutics
Apple Tree Partners
Apple Tree Partners, operating ATP RD Labs, is an incubator and accelerator focused on foundational science. They provide comprehensive services including compound screening, cellular and molecular assays, and preclinical pharmacology to discover and evaluate small molecules.
What's next for Initial Therapeutics?
With the recent influx of major strategic investment, Initial Therapeutics is poised for accelerated development and expansion. The capital infusion is expected to fuel the advancement of its drug discovery and development programs, potentially enabling the company to move key candidates through preclinical and clinical stages. This strategic financing will likely support the scaling of its research operations and the expansion of its scientific team, reinforcing its commitment to bringing its novel medicines to patients.
See full Initial Therapeutics company page
